Soleus Capital Management L.P. Trims Stake in Evolus, Inc. (NASDAQ:EOLS)

Soleus Capital Management L.P. reduced its holdings in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 32.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 697,158 shares of the company's stock after selling 340,522 shares during the quarter. Soleus Capital Management L.P. owned approximately 1.10% of Evolus worth $7,697,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of EOLS. KBC Group NV bought a new stake in Evolus during the fourth quarter worth $49,000. IFP Advisors Inc raised its stake in shares of Evolus by 17,440.7% in the fourth quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock valued at $52,000 after buying an additional 4,709 shares during the period. KLP Kapitalforvaltning AS bought a new stake in shares of Evolus in the fourth quarter valued at $106,000. Rafferty Asset Management LLC bought a new stake in shares of Evolus in the fourth quarter valued at $115,000. Finally, Quantbot Technologies LP bought a new stake in shares of Evolus in the fourth quarter valued at $118,000. 90.69% of the stock is currently owned by institutional investors.

Insider Activity

In related news, insider Rui Avelar sold 3,385 shares of the business's stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $9.87, for a total transaction of $33,409.95. Following the completion of the transaction, the insider now directly owns 359,082 shares in the company, valued at $3,544,139.34. The trade was a 0.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Karah Herdman Parschauer sold 12,888 shares of the business's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $12.99, for a total value of $167,415.12. Following the transaction, the director now owns 32,183 shares of the company's stock, valued at approximately $418,057.17. The trade was a 28.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 86,241 shares of company stock worth $1,048,666. 5.90% of the stock is owned by corporate insiders.

Evolus Stock Performance

Shares of NASDAQ EOLS traded up $0.12 during mid-day trading on Friday, hitting $9.68. The company had a trading volume of 462,704 shares, compared to its average volume of 693,032. The company has a market capitalization of $624.13 million, a price-to-earnings ratio of -10.64 and a beta of 1.11. Evolus, Inc. has a 1 year low of $8.67 and a 1 year high of $17.82. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The stock's 50-day moving average price is $10.97 and its 200-day moving average price is $12.13.

Analyst Ratings Changes

Several brokerages have issued reports on EOLS. Barclays boosted their target price on Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Needham & Company LLC restated a "buy" rating and issued a $22.00 target price on shares of Evolus in a research note on Thursday, May 8th. BTIG Research began coverage on Evolus in a research note on Thursday, April 17th. They issued a "buy" rating and a $21.00 target price on the stock. Finally, HC Wainwright restated a "buy" rating and issued a $27.00 target price on shares of Evolus in a research note on Thursday, April 10th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $23.75.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.